Flash Finance

Glenmark Pharmaceuticals LimitedGLENMARKCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹2,226.70
MCap ₹62,843 Cr · P/E 35.0
Glenmark Pharmaceuticals Limited — Stock analysis & AI research Glenmark Pharmaceuticals Limited — Multibagger AI analysis Glenmark Pharmaceuticals Limited — Seasonality — best & worst months Glenmark Pharmaceuticals Limited — Technical indicators & charts Glenmark Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Glenmark Pharmaceuticals Limited — Triple Top pattern forming Glenmark Pharmaceuticals Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 GARP Stocks (PEG Below 1)📋 Low Debt Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹4,018 Cr
Sales · Jun 2026
+23.1% YoY
₹805 Cr
Operating Profit · Jun 2026
+38.6% YoY
20.0%
OPM % · Jun 2026
+12.4% YoY
₹483 Cr
Net Profit · Jun 2026
+927.9% YoY
₹17.11
EPS · Jun 2026
+930.7% YoY

📝 Glenmark Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Glenmark Pharmaceuticals Limited reported revenue of ₹4,018 crore for the quarter ended June 2026 (Q1 FY27), up 23.1% from ₹3,264 crore in the same quarter last year, and up 6.6% sequentially over the March 2026 quarter.

Net profit rose 927.9% year-on-year to ₹483 crore, from ₹47 crore. Earnings per share (EPS) came in at ₹17.11.

Operating profit stood at ₹805 crore — an operating margin (OPM) of 20.0%, compared with 17.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Glenmark Pharmaceuticals Limited posted revenue of ₹16,983 crore, a decline of 61.2% over FY25, with a net profit of ₹1,362 crore (down 67.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹17,737 crore with a net profit of ₹1,797 crore.

Valuation snapshot

At the current price of ₹2,226.70, GLENMARK has a market capitalisation of ₹62,843 crore and a trailing P/E of about 35.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 11th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 46.65%, foreign institutional investors (FIIs) 20.35%, domestic institutional investors (DIIs) 19.28%, the government 0.04%, public shareholders 13.70% of Glenmark Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹62,843 Cr
Current Price ?
₹2,226.7
P/E ?
34.96below ind
Industry P/E ?
35.00
P/B ?
5.98
P/S ?
3.54
P/FCF ?
30.07
Enterprise Value ?
₹63,437 Cr
EV/EBITDA ?
13.22
PEG ?
0.46
Earnings Yield ?
6.6%
Dividend Yield ?
0.12%
Profitability & Returns
Sales (TTM) ?
₹17,737 Cr
OPM ?
27.0%
Profit after tax (TTM) ?
₹1,797 Cr
EPS (TTM) ?
₹63.69
ROCE ?
40.0%
ROE ?
17.1%
ROA ?
9.0%
Growth
Sales — latest qtr ?
₹4,018 Cr
PAT — latest qtr ?
₹483 Cr
YoY qtr sales growth ?
23.1%
YoY qtr profit growth ?
927.9%
Sales growth (3y) ?
14%
Sales growth (5y) ?
9%
Profit growth (3y) ?
76%
Profit growth (5y) ?
26%
Financial Health
Debt ?
₹594 Cr
Debt to Equity ?
0.06
Interest Coverage ?
19.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
46.65%
Change in promoter holding ?
0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
-0.4%
Return 6 months ?
-1.0%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 3,4643,0013,4023,2072,5073,0633,2443,43433,8763,2563,2646,0473,9013,7714,018 +23.1% +6.6%
Operating Profit 620398631462-2095045886026,0025615812,360870763805 +38.6% +5.5%
Other Income 76-69621-205873513139311-3612620144-18466 +148.7% +135.7%
Interest 971091121211341494048523675866414354 -7.3% +25.6%
Depreciation 1621351551411471511181201,227125130141154148173 +33.3% +17.0%
Profit Before Tax 471-542333-6-4035554624734,563896967534388643 +573.1% +65.8%
Net Profit 291-403173-62-331-1,2143403543,480447610403301483 +927.9% +60.4%
EPS 9.66-15.185.31-2.90-12.45-43.1712.0612.5512.330.161.6621.6314.2910.6817.11 +930.7% +60.2%
OPM % 17.9% 13.3% 18.6% 14.4% -8.3% 16.5% 18.1% 17.5% 17.7% 17.2% 17.8% 39.0% 22.3% 20.2% 20.0% +12.4% -1.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹43,810 Cr ₹16,983 Cr ₹17,737 Cr -61.2%
Operating Profit ₹7,754 Cr ₹4,573 Cr ₹4,797 Cr -41.0%
OPM % 17.70% 26.93% 27.05% +52.1%
NPM % 9.54% 8.02% 10.13% -15.9%
Other Income ₹21 Cr ₹88 Cr ₹127 Cr +321.4%
Depreciation ₹1,590 Cr ₹574 Cr ₹617 Cr -63.9%
Interest ₹678 Cr ₹209 Cr ₹205 Cr -69.1%
EBIT ₹6,163 Cr ₹3,999 Cr ₹4,180 Cr -35.1%
PBT ₹5,507 Cr ₹1,985 Cr ₹2,533 Cr -64.0%
Tax ₹1,205 Cr ₹536 Cr ₹648 Cr -55.5%
Net Profit ₹4,179 Cr ₹1,362 Cr ₹1,797 Cr -67.4%
EPS ₹37.10 ₹48.26 ₹63.71 +30.1%
Material Cost ₹12,691 Cr ₹4,181 Cr ₹4,129 Cr -67.1%
Employee Cost ₹8,595 Cr ₹2,690 Cr ₹2,862 Cr -68.7%
Extraordinary Items — ₹1,893 Cr ₹1,569 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 28282828 +0.0%
Reserves 9,4467,8208,82110,484 +18.9%
Borrowings 4,6081,2312,473594 -76.0%
Other Liabilities 5,2895,2794,6698,802 +88.5%
Total Liabilities 19,37114,35815,99119,908 +24.5%
Fixed Assets 5,4224,2104,4876,396 +42.5%
CWIP 1,190662835428 -48.7%
Investments 457905642 -25.0%
Other Assets 12,7158,69710,61313,042 +22.9%
Total Assets 19,37114,35815,99119,908 +24.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 625-265-8283,445 +516.1%
Cash from Investing Activity -5154,38758-1,283 -2312.1%
Cash from Financing Activity -77-3,906787-2,709 -444.2%
Net Cash Flow 3221517-547 -3317.6%
Free Cash Flow 75-1,162-1,5752,090 +232.7%
CFO/OP 77%65%-6%92% +1633.3%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 1155792107 +16.3%
Inventory Days 203208254264 +3.9%
Days Payable 172210216288 +33.3%
Cash Conversion Cycle 1475612983 -35.7%
Working Capital Days 141-24481 +84.1%
ROCE % 10%12%19%40% +110.5%

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 46.64%46.64%46.65%46.65% +0.0%
FIIs 20.62%20.73%19.20%20.35% +6.0%
DIIs 17.64%18.61%20.09%19.28% -4.0%
Government 0.04%0.04%0.04%0.04% +0.0%
Public 15.05%13.97%14.02%13.70% -2.3%
No. of Shareholders 1,90,2101,98,7892,01,5841,96,105 -2.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Glenmark Pharmaceuticals Limited's revenue in Q1 FY27?
Glenmark Pharmaceuticals Limited reported revenue of ₹4,018 crore for the quarter ended June 2026 (Q1 FY27), up 23.1% from ₹3,264 crore in the same quarter last year, and up 6.6% sequentially over the March 2026 quarter.
What was Glenmark Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit rose 927.9% year-on-year to ₹483 crore, from ₹47 crore. Earnings per share (EPS) came in at ₹17.11.
What is GLENMARK's market capitalisation and P/E ratio?
At the current price of ₹2,226.70, GLENMARK has a market capitalisation of ₹62,843 crore and a trailing P/E of about 35.0.
Who owns Glenmark Pharmaceuticals Limited? (shareholding pattern)
As of Mar 2026, promoters held 46.65%, foreign institutional investors (FIIs) 20.35%, domestic institutional investors (DIIs) 19.28%, the government 0.04%, public shareholders 13.70% of Glenmark Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI